AUTH/2208/2/09: Health professional v Gilead Sciences – unsolicited email about fellowship programme (no breach)

📅 2009 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2208/2/09
Case referenceHealth professional v Gilead Sciences; Unsolicited email
ComplainantHealth professional
Respondent/companyGilead Sciences Ltd
Product(s)Not stated
Material/channelEmail (with attached letter)
Key issueUnsolicited email to a personal address advertising a Gilead-sponsored fellowship programme; whether this breached restrictions on email promotion and high standards
Dates (received/completed if stated)Complaint received 16 February 2009; Case completed 23 March 2009
AppealNot stated
Code yearNot stated
Breaches/clausesNo breach of Clause 9.9; No breach of Clause 9.1
SanctionsNo explicit additional sanctions stated beyond the required undertaking/corrective actions described in the report

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
📋

What happened

  • A health professional complained he received an unsolicited email from Gilead Sciences Ltd and said he had not provided his email address to Gilead.
  • He asked Gilead how it obtained his personal email address and requested confirmation it would be removed from the mailing list; he said he received no reply.
  • The email advertised the Gilead UK and Ireland Fellowship Programme; it did not relate to a particular product.
  • Gilead said the email was non-promotional, sent by the medical director to a broad group of health professionals, and the complainant’s address was inadvertently included.
  • Gilead said it sent an apology on 30 January 2009 confirming removal from the distribution list, but it appeared this did not reach the complainant.
  • The fellowship programme was described as a new initiative to largely replace an existing grants process, supporting best practice in HIV, invasive fungal disease and chronic hepatitis B.
⚖️

Outcome

  • The Panel ruled the email was non-promotional and therefore there was no breach of Clause 9.9.
  • The Panel found that Gilead replied to the complainant’s removal request and considered high standards had been maintained; no breach of Clause 9.1 was ruled.
  • Overall outcome: No breach of the Code.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Charter Member — Until 31 March

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export. £1,999/year £2,499

Get Charter Access →

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free